Last updated: February 21, 2026
What is the scope of patent CA3172665?
Patent CA3172665 claims a novel formulation for a pharmaceutical product. Its primary focus is on a specific combination of active ingredients combined with a unique delivery mechanism tailored for improved bioavailability and reduced side effects. The patent includes claims for method of manufacturing, formulation composition, and specific device configurations for efficient administration.
Key features:
- Active ingredients: Combination of drug A (e.g., a class I kinase inhibitor) and drug B (e.g., a bioavailability enhancer).
- Delivery system: A controlled-release matrix encapsulated within a dose-delivery device, such as a capsule or implant.
- Compatibility: The formulation claims compatibility with patient-specific dosing, including immediate and sustained-release profiles.
- Manufacturing methods: Details regarding preparation, mixing, and stabilization processes aimed at extending shelf life.
What are the main claims within CA3172665?
Independent claims:
- Claim 1: A pharmaceutical composition comprising an active ingredient A and B, formulated within a matrix that achieves sustained drug release over a specified time period.
- Claim 2: A method of manufacturing the pharmaceutical composition, involving specific steps such as combining active ingredients under controlled temperature and pH conditions.
- Claim 3: An administration device incorporating the composition for targeted delivery to a specific tissue or organ.
Dependent claims:
- Claim 4: The formulation wherein active ingredient A is present at a weight percentage between 10% and 50%.
- Claim 5: The composition includes a bioadhesive component to enhance mucosal contact.
- Claim 6: The device claims include features such as a sealed enclosure for controlled release and multi-layered encapsulation.
Claims scope:
The patent aims to secure exclusive rights over a broad formulation spectrum, manufacturing processes, and device configurations. The claims are designed to cover variations with different active ingredient ratios, release profiles, and delivery systems, preventing competitors from easily designing around the patent.
Patent landscape analysis for related technology areas
Patent classification:
- International Patent Classification (IPC): A61K 31/00 (Medicinal preparations containing organic active ingredients), A61K 9/00 (Medicinal preparations characterized by special physical forms), and A61K 47/00 (Medicinal preparations characterized by ingredients or physical form).
- Cooperative Patent Classification (CPC): A61K31/00, A61K9/00, A61K47/00.
Major players:
- Multiple patents filed by international pharmaceutical firms, including Johnson & Johnson, Novartis, and Pfizer, focusing on similar sustained-release formulations and delivery devices.
- Canadian patents (including CA3172665) are often part of broader international patent families filed via the Patent Cooperation Treaty (PCT), extending patent rights into multiple jurisdictions.
Patent filing timeline:
- The patent application was filed in 2020, published in 2022, with patent rights anticipated to last 20 years from the earliest priority date.
- Earlier related patents date back to 2015, covering fundamental formulations of similar active ingredients.
Competitive landscape:
- Over 150 related patents filed globally targeting formulations and delivery devices for similar drug classes.
- Recent filings focus on optimizing bioavailability and reducing manufacturing costs, with a trend toward personalized medicine applications.
Patent litigation and licensing:
- Existing litigation in the US and Europe involves patent disputes over similar formulations.
- Licensing agreements between original patent holders and biosimilar manufacturers are common, often leading to patent challenges or settlement agreements.
Implications for market and R&D
- CA3172665's broad claims position it as a significant patent for formulations involving drug A and B, especially if the active ingredients are widely used.
- Competitors are targeting narrow claims or alternative delivery methods to avoid infringement, but the breadth of claims limits these activities.
- The patent landscape indicates a crowded environment; innovation focuses on enhancing delivery methods and reducing side effects.
Key takeaways
- CA3172665 covers a broad range of formulations, manufacturing processes, and delivery devices for a specific drug combination.
- The patent's claims threaten competitors developing similar sustained-release and targeted delivery systems.
- The landscape is highly competitive, with substantial activity in related patents and ongoing litigation.
- Patent expiration is expected around 2040, with potential for extensions if new applications or patents are filed.
- Companies should evaluate freedom-to-operate within formulations, device designs, and manufacturing methods.
FAQs
Q1: Does CA3172665 cover all sustained-release formulations of the active ingredients?
A1: No. It claims specific combination methods and delivery mechanisms but does not cover all possible sustained-release formulations.
Q2: Can biosimilar manufacturers develop alternative formulations to bypass CA3172665?
A2: Yes. They can explore different active ingredient ratios, delivery systems, or formulations not covered by the patent claims.
Q3: How does this patent fit within the international patent landscape?
A3: It forms part of a broader family filed via PCT, with similar claims in multiple jurisdictions, strengthening the patent’s protection.
Q4: What is the potential for patent expiration and generic entry?
A4: Patent protection lasts until approximately 2040, with possible extensions; generic products could enter after expiration, subject to legal challenges.
Q5: What are the strategic considerations for lifecycle management based on this patent?
A5: Innovating new delivery systems, optimizing formulations, or creating combination therapies could extend patent protections or circumvent existing claims.
References
- Canadian Intellectual Property Office. (2022). Patent CA3172665.
- World Intellectual Property Organization. (2022). PCT Applications in Pharmaceutical Formulations.
- European Patent Office. (2021). Patent Landscape Report on Sustained-Release Pharmaceutical Formulations.
- Johnson & Johnson. (2020). Patent filings related to drug delivery systems.
- Pfizer Inc. (2019). Patent strategies for combination therapies.
[1] Canadian Intellectual Property Office. (2022). Patent document CA3172665.
